8-K: BIO-key Secures $3.1M, Eliminates Secured Debt

BIO-key International raised $3.1 million in gross proceeds from a warrant exercise and fully repaid a $2.36 million secured note through a debt-for-equity exchange.

Summary

• BIO-key International, Inc. (BKYI) entered into a warrant exercise agreement with an institutional investor on October 27, 2025.
• The investor exercised 3,091,668 existing warrants, originally issued on January 15, 2025, with the exercise price reduced from $2.15 to $1.02 per share.
• The company received approximately $3.1 million in gross proceeds from this warrant exercise.
• In consideration for the exercise, the investor received 6,183,336 new unregistered common stock purchase warrants, exercisable at $1.02 per share and expiring in October 2030.
• The company also entered into two exchange agreements with Streeterville Capital, LLC on October 27, 2025.
• These agreements partitioned two promissory notes totaling $327,991.35 from an original $2,360,000 secured note dated June 24, 2024.
• The partitioned notes were exchanged for an aggregate of 429,027 shares of the company's common stock, resulting in the full repayment of the original secured note.
• Maxim Group LLC acted as the exclusive placement agent for the warrant exercise, receiving a 6.0% cash fee of the gross proceeds.

Sentiment

Score: 6

Explanation: While the company successfully raised capital and eliminated a secured debt, the significant dilution from new warrants and exchange shares, coupled with the reduction in exercise price for existing warrants, suggests a need to incentivize investors and indicates potential financial strain. The capital raise addresses immediate needs but comes at a cost to existing shareholders.

Positives

• Secured approximately $3.1 million in gross proceeds, enhancing working capital and general corporate purposes.
• Successfully eliminated a $2.36 million secured promissory note through a debt-for-equity exchange, improving the balance sheet.
• The reduction in the exercise price of existing warrants to $1.02 per share incentivized the investor to exercise, bringing in immediate capital.
• The new warrants issued have an exercise price of $1.02, potentially making them more attractive for future exercise by the holder.

Negatives

• Significant dilution for existing shareholders due to the issuance of 6,183,336 new warrants and 429,027 exchange shares.
• The reduction of the exercise price for existing warrants from $2.15 to $1.02 per share suggests a need to incentivize investors, potentially indicating a lower perceived value or financial pressure.
• A 6.0% placement agent fee was paid to Maxim Group LLC on the $3.1 million gross proceeds, reducing the net capital raised.
• The new warrants are unregistered, requiring the company to file a resale registration statement and use commercially reasonable efforts to get it effective within 90 days, incurring additional costs and regulatory burden.

Risks

• Dilution Risk: The issuance of new warrants and exchange shares will dilute the ownership percentage of existing shareholders.
• Market Price Volatility: The warrant exercise and debt-for-equity swap, especially with a reduced exercise price, could signal market concerns or put downward pressure on the stock price.
• Registration Risk: Failure to get the resale registration statement for the new warrant shares effective within 90 days could lead to liquidated damages and further investor dissatisfaction.
• Beneficial Ownership Limitation: The 4.99% (or 9.99%) beneficial ownership limitation on the new warrants could restrict the investor's ability to fully exercise warrants at once, potentially delaying full capital infusion or market impact.
• Liquidity Risk: The company's need for working capital and debt repayment suggests ongoing liquidity management challenges, despite the current capital raise.

Future Outlook

The company plans to use the net proceeds from the warrant exercise for working capital and general corporate purposes, including the repayment of a portion of its outstanding secured note. It also committed to filing a resale registration statement for the new warrant shares within 90 calendar days and using commercially reasonable efforts to ensure its effectiveness.

Management Comments

• The filing was signed by Cecilia C. Welch, Chief Financial Officer, indicating management's formal acknowledgment of these transactions.

Industry Context

These transactions reflect a common strategy for smaller public companies to raise capital and manage debt, often involving warrant exercises and debt-for-equity swaps. The reduction in warrant exercise price and issuance of new warrants are typical incentives used to encourage capital infusion in challenging market conditions or for companies seeking to strengthen their balance sheet. The use of a placement agent like Maxim Group LLC is standard practice for such capital-raising efforts.

Stakeholder Impact

• Shareholders: Experience dilution from the issuance of new warrants and exchange shares. Potential for future dilution upon exercise of new warrants.
• Creditors: Streeterville Capital, LLC's secured note has been fully repaid, improving the company's debt profile with this specific lender.
• Company: Improved liquidity with $3.1 million in gross proceeds and reduced debt burden.

Next Steps

• File a resale registration statement covering the public resale of shares issuable upon exercise of the new warrants.
• Use commercially reasonable efforts to have the resale registration statement declared effective by the SEC within 90 calendar days.
• Apply to list or quote all new warrant shares on the Nasdaq Capital Market.
• Maintain the listing or quotation of Common Stock on the Trading Market.
• Maintain eligibility of Common Stock for electronic transfer through The Depository Trust Company.

Key Dates

Recommendation

The company successfully addressed immediate capital and debt obligations, which is a positive. However, the significant dilution from the warrant exercise and debt-for-equity swap, coupled with the reduced exercise price, suggests underlying financial challenges. While the immediate liquidity is improved, the long-term impact of dilution and the need for such incentivized financing warrant a cautious 'hold' stance until further operational improvements or clearer strategic direction are demonstrated.

Keywords

BIO-key International, BKYI, Warrant Exercise, Debt Restructuring, Equity Financing, SEC Filing, Form 8-K, Common Stock, Promissory Note, Dilution, Capital Raise, Streeterville Capital, Armistice Capital, Maxim Group